Devita, Hellman, and Rosenberg's Cancer

LWBK1006-44 LWW-Govindan-Review November 24, 2011 11:30

CHAPTER 44 MANAGEMENT OF

ADVERSE EFFECTS OF

TREATMENT

MARIA Q. BAGGSTROM

DIRECTIONS Each of the numbered items below is followed by lettered answers. Select the

ONE lettered answer that is BEST in each case unless instructed otherwise.

QUESTIONS

Question 44.1. A 40-year-old woman with breast cancer is receiving adjuvant chemother-

apy with dose dense AC (doxorubicin and cyclophosphamide) with peg-

filgrastim support. After 3 cycles of chemotherapy, she presents to the

emergency room with left upper quadrant abdominal pain, and is found

to be hypotensive and anemic with a hemoglobin of 9 g/dL. The most

likely reason for her anemia is:

A. Chemotherapy

B. Splenic rupture

C. Disease progression

D. Iron deficiency

Question 44.2. Primary prophylactic G-CSF administration is recommended in which

cases?

A. Chemotherapy regimens in which the expected incidence of febrile

neutropenia is 20% or greater.

B. A decrease in dose intensity would compromise long-term outcomes,

such as survival or cure.

C. The patient is at increased risk for serious complications or death

from febrile neutropenia.

D. All of the above are true.

Corresponding Chapters inCancer: Principles & Practice of Oncology,Ninth Edition: 158 (Cancer-Associated

Thrombosis), 159 (Nausea and Vomiting), 160 (Diarrhea and Constipation), 161 (Oral Complications), 162 (Pul-

monary Toxicity), 163 (Cardiac Toxicity), 164 (Hair Loss), 165 (Gonadal Dysfunction), 166 (Fatigue), 167 (Second

Primary Cancers), 168 (Neurocognitive Effects), and 169 (Cancer Survivorship).

551